Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The companys commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The companys pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohns and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog30 Aug 2014, 8:31 amOn Aug 26, 2014, we issued an updated research report on RegeneronPharmaceuticals ( REGN ). The biopharmaceutical company reported earnings of $1.89 per share in the second quarter of 2014, missing the Zacks Consensus Estimate of $2.33 by a
The Zacks Analyst Blog Highlights: InterMune, Kite Pharma, Amicus, Celgene and Bristol-Myers Squibb28 Aug 2014, 6:20 amThe Zacks Analyst Blog Highlights: InterMune, Kite Pharma, Amicus, Celgene and Bristol-Myers Squibb
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog27 Aug 2014, 10:07 amBiotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Stock Market News for August 26, 2014 - Market News26 Aug 2014, 10:28 amStock Market News for August 26, 2014 - Market News
Stock Market News for August 26, 201426 Aug 2014, 7:32 amThe S&P 500 closed at a record high and fellow benchmarks also ended in the green boosted by deal news
3 Reasons Celgene Corporation's Stock Could Fall26 Aug 2014, 7:10 am3 Reasons Celgene Corporation's Stock Could Fall
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog22 Aug 2014, 5:08 pmThe key growth driver at Celgene Corporation ( CELG ) is Revlimid. The drug, already available for multiple oncology indications, recorded sales of $1.2 billion in the second quarter of 2014, up 15% over the year ago period. The
Biotech Stock Mailbag: Threshold, Galena, CytRx22 Aug 2014, 1:48 pmBiotech columnist Adam Feuerstein answers readers' questions about health care. Click to view a price quote on THLD . Click to research the Drugs industry.
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog21 Aug 2014, 4:12 pmBristol Myers Squibb Company ( BMY ) entered into a collaboration with Celgene Corporation ( CELG ) to asses the safety, tolerability and preliminary efficacy of a cocktail therapy including its high potential immuno oncology drug Opdivo (nivolumab, a
Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver5 Aug 2014, 8:23 amCHICAGO, Aug. 5, 2014 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, CELG, WB, SPWR, and TWX. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note:...